Allo-hMSCs

BIOLOGICAL4 trials

Sponsors

University of Miami, Longeveron Inc., Joshua M Hare

Conditions

Cystic FibrosisHypoplastic Left Heart SyndromeStem Cell TransplantationTreatment Resistant Depression

Phase 1

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

CompletedNCT01087996

University of MiamiStem Cell Transplantation

Start: 2010-03-31End: 2012-10-31Updated: 2015-05-27

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

TerminatedNCT02398604

Longeveron Inc.Hypoplastic Left Heart Syndrome

Start: 2015-04-30End: 2019-03-31Updated: 2021-07-19

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

TerminatedNCT02675556

Joshua M HareTreatment Resistant Depression

Start: 2017-10-31End: 2019-03-26Updated: 2019-04-01

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

WithdrawnNCT03058068

Joshua M HareCystic Fibrosis

Start: 2020-12-31End: 2028-09-30Updated: 2020-05-13

Related Papers

Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.

2018-07-1228 citations

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.

2012-12-01879 citations